Mistral Pharma

Mistral Pharma Inc. was a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec, that focused on the development and commercialization of value-added products using advanced drug delivery technologies. The company primarily targeted therapeutic areas such as urology, cardiovascular health, and pain management, utilizing a business model that enhanced existing drug molecules to improve patient outcomes. Its lead product, Umax, was a controlled-release formulation of alfuzosin indicated for the treatment of benign prostatic hyperplasia. Mistral was publicly traded on the TSX Venture Exchange under the symbol MPI. Following financial challenges in the mid-2000s, the company's key urology assets were acquired by Bioniche Life Sciences, and the company eventually ceased operations following asset liquidation.